ArticleSleep medicine2014
Medications associated with restless legs syndrome: a case-control study in the US Renal Data System (USRDS).
Article in Sleep medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 42 citations in OpenAlex.
- Restless Legs Syndrome Associated With Fexofenadine Use: A Case Report.Clinical case reports · 2026Article
- Exploring the Top 50 Drugs Associated with Restless Legs Syndrome Based on the FDA Data from 2004 to 2024.Nature and science of sleep · 2025Article
- Association between Chronic kidney disease and restless leg syndrome (RLS): a systematic review and meta-analysis.Sleep and biological rhythms · 2024Article
- Review of the role of the endogenous opioid and melanocortin systems in the restless legs syndrome.Brain : a journal of neurology · 2024Article
- Restless legs syndrome in chronic renal failure patients on dialysis.African health sciences · 2023Article
- Dopamine agonists and risk of lung cancer in patients with restless legs syndrome.Pharmacoepidemiology and drug safety · 2023Article
- Restless leg syndrome in spinal cord injury: case report.Spinal cord series and cases · 2023Article
- Using Named Entity Recognition to Identify Substances Used in the Self-medication of Opioid Withdrawal: Natural Language Processing Study of Reddit Data.JMIR formative research · 2022Article
- Nighttime Agitation in Persons with Dementia as a Manifestation of Restless Legs Syndrome.Journal of the American Medical Directors Association · 2021Observational
- Restless legs syndrome induced by fexofenadine/pseudoephedrine.Journal of general and family medicine · 2020Article
- [Update on restless legs syndrome].Der Nervenarzt · 2020Article
- Restless Legs Syndrome across the Lifespan: Symptoms, Pathophysiology, Management and Daily Life Impact of the Different Patterns of Disease Presentation.International journal of environmental research and public health · 2020Review
- Review
- Neuropathic Pain and Sleep: A Review.Pain and therapy · 2017Review
- Individuals with Restless Legs Syndrome Tend to have Severe Depressive Symptoms: Findings from a Community-Based Cohort Study.Psychiatry investigation · 2017Article
- Association of restless legs syndrome and mortality in end-stage renal disease: an analysis of the United States Renal Data System (USRDS).BMC nephrology · 2017Article
- Thr105Ile (rs11558538) polymorphism in the histamine-1-methyl-transferase (HNMT) gene and risk for restless legs syndrome.Journal of neural transmission (Vienna, Austria : 1996) · 2017Article
- Sleep and Pain in Pediatric Illness: A Conceptual Review.CNS neuroscience & therapeutics · 2016Review
- A practical approach to the diagnosis and management of sleep disorders in patients with multiple sclerosis.Therapeutic advances in neurological disorders · 2015Review
- Risk of Restless Legs Syndrome Following Tension-Type Headache: A Nationwide Population-Based Cohort Study.Medicine · 2015Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
objectiveThe objective of this study was to determine the association between the usage of four classes of "at-risk" medications (antidepressants, neuroleptics, antihistamines, and antiemetics with dopamine blockade) and restless legs syndrome (RLS) in dialysis patients within the United States Renal Data System (USRDS).
methodsThis was a case-control design within a national (United States) patient registry of all patients with end-stage renal disease (ESRD) in the USRDS anytime during the period of 1 October 2006 to 31 December 2010, inclusive. A total of 16,165 ESRD patients (3234 cases; 12,931 age-, sex-, and race-matched controls) were studied.
resultsAll four classes of "at-risk" medications see widespread use among patients in the USRDS. All were associated with increased odds of an RLS diagnosis (range of odds ratios, 1.47-2.28; all p < 0.0001) during the period of observation. Results were unchanged when controlling for time on hemodialysis. Usage of more than one class of medication increased the odds for having RLS.
conclusionsESRD patients often receive medication intended for relief of conditions associated with their disease, such as depression and psychological issues, pruritus, and gastroparesis; however, such medications may increase the risk of RLS. Given the high prevalence of RLS in ESRD patients, these medications should only be used when their benefits clearly outweigh the risk of development of the troubling and distressing symptoms of RLS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.